• Online Data Supplement P ulmonary hypertension (PH) is defined as a resting mean pulmonary artery (PA) pressure (mPAP) ≥25 mm Hg, which is roughly double the normal mPAP. 1 The breadth and inclusivity of this definition is problematic for several reasons. First, PH is a heterogeneous syndrome with variable etiologies, therapies, and prognosis. Thus, a diagnosis of PH does not guide therapy, although it does portend poor prognosis. Second, mPAP is rarely measured directly because this requires right heart catheterization. In clinical practice, right ventricular (RV) systolic pressure (RVSP) is usually estimated from noninvasive Doppler measurement of the peak velocity of a tricuspid regurgitation jet using the Bernoulli equation. This estimate is fraught with difficulties, including inaccuracy and an intrinsic inability to distinguish whether PH is caused by pulmonary vascular disease versus left ventricular (LV) diastolic dysfunction. Although pulmonary vascular disease can be identified and mPAP calculated from the PA Doppler signal (by measuring PA acceleration time 2 ; Figure 1 ), this simple measurement is often omitted.
To facilitate clinical categorization and management of PH patients, the 1998 World Symposia on Pulmonary Hypertension divided PH into 5 groups. The latest update in 2013 modified the taxonomy; however, the 5 major groups are unchanged. 1 Group 1 PH or pulmonary arterial hypertension (PAH) is an orphan disease, with an estimated prevalence of 10 to 52 cases/million adults. 3 Group 1 PH, defined as an mPAP≥25 mm Hg with pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg and pulmonary vascular resistance (PVR) >3 Wood units, 4 has received the most attention. Preclinically, there are robust animal models of group 1 disease and a related basic science knowledge base. Clinically, these patients are managed in specialized clinics and are treated with 4 classes of approved PH-targeted therapies. 3 There has been a remarkable increase in our knowledge of the molecular mechanisms underlying group 1 PH over the past decade. [5] [6] [7] In contrast, there are far fewer preclinical models and a less detailed understanding of the molecular mechanisms of the other PH groups. Most World Health Organization (WHO) group 2 to 4 patients are not managed in specialized, groupfocused PH clinics, which is also an impediment to progress.
Group 2 is the most prevalent form of PH and is usually caused by valvular or myocardial left heart disease. 3 An echocardiography-based epidemiological study from Australia estimates the prevalence of group 2 PH at 250 cases/100 000 population 8 and group 3 PH at 37 cases/100 000 population. 8 Group 4 PH, also known as chronic thromboembolic PH (CTEPH), has an incidence similar to group 1 disease. 9 German and French PH registries suggest that the annual incidence of CTEPH is 4 and 6 cases/million adults/ year, respectively. 10 Because group 5 PH is a heterogeneous collection of PH syndromes, the search for common intragroup mechanisms is most applicable to WHO groups 1 to 4.
The WHO PH classification is based on clinical phenotype (hemodynamics, comorbidities, and histology) rather than pathological cellular and molecular mechanisms, such as endothelial dysfunction, inflammation/immunity, and mitochondrial dysfunction. [11] [12] [13] [14] Some molecular mechanisms, such as endothelial dysfunction, are shared across PH groups. For instance, in group 2 PH caused by mitral stenosis (MS), the initiating pathophysiological stimulus is retrograde transmission of elevated left atrial pressure and the resulting pulmonary venous hypertension. 15 PH occurs in 78% of MS patients. 15 PH in MS may be proportional or disproportional. In a proportional PH response, the elevation of mPAP is at the minimum level required for antegrade circulation. In such cases, right heart catheterization reveals a minimal gap between PA diastolic pressure and PCWP. However, in MS patients with disproportionate PH, there is a large PA diastolic pressure-PCWP gap, and their hemodynamics have some commonality with group 1 patients, notably elevated PVR. This reflects adverse pulmonary vascular remodeling or pulmonary vasoconstriction. Mitral valve replacement may not immediately cure PH in disproportionate responders because it does not address their residual pulmonary vascular disease. Indeed, 42% to 64% of MS patients have persistent PH after successful mitral valve surgery ( Figure 2 ).
MS patients. He showed that PVR could be halved acutely with infusion of acetylcholine (Figure 3) , 18 an endotheliumdependent vasodilator, which causes synthesis of nitric oxide (NO) 19 and endothelium-derived hyperpolarizing factor. 20 In addition to vasoconstriction, some MS patients have disproportionate PH because of adverse pulmonary vascular remodeling, with thickening of the intima and media of small PAs (Figure 4) . 21 Thus, individual variations in endothelial function and vascular remodeling likely contribute to the susceptibility of patients with left heart disease (LHD) to group 2 PH. 17 The fact that these disproportionate responders have some physiological similarities to group 1 patients suggests that it may be profitable to examine molecular pathways that are disordered in group 1 PH for potential relevance to other PH groups.
This review explores our current understanding of the preclinical models, underlying molecular pathways, and potential new therapeutic targets for group 2, 3, and 4 PH. We will begin with a review of the preclinical models for each PH group.
Preclinical Rodent PH Models
Rodent models of PH are most frequently used because of their low cost, convenience, rapidity, and the greater societal acceptance of the ethics of using rodents versus large animals in research. Thus, most of our understanding of the molecular mechanisms responsible for PH is derived from rodent PH models.
Models of Group 1 PH
Although this review is focused on group 2 to 4 PH, we briefly discuss the most widely used group 1 rodent PH models because group 2 to 4 PH models share disorders of some of the same molecular pathways.
Monocrotaline-Induced PAH
Monocrotaline (MCT) is derived from the plant Crotalaria spectabilis. CYP3A4-dependent hepatic metabolism creates a reactive MCT pyrrole, which causes endothelial damage. A single dose of MCT (60-100 mg/kg, subcutaneously) reliably causes PH in rats within 3 to 4 weeks and leads to death from RV failure within 6 to 8 weeks. 22 The MCT rodent model recapitulates many features of human PAH, such as early endothelial injury, generation of reactive oxygen species, adverse pulmonary vascular remodeling, increased mitochondria fission, and mitochondrial metabolic abnormalities in the pulmonary vasculature and RV. 22 However, critics of the model point out that MCT's systemic toxicities (hepatotoxicity, cardiac toxicity, immunotoxicity, and DNA crosslinking) 23 and the absence of plexiform lesions on lung histology make it an imperfect approximation of human PAH. 22 However, the MCT model does display all other histological features of group 1 PH, such as medial hypertrophy and intimal hyperplasia, and the animals die from RV failure, as do group 1 patients.
Sugen 5416-Hypoxia Model
Sugen 5416 (SU) is an inhibitor of VEGF (vascular endothelial growth factor) receptor 2. A PAH model was initially created by subcutaneous injection of adult male SpragueDawley rats with SU5416 (200 mg/kg, 3× per week for 3 weeks). At Denver, Colorado's altitude (≈1600 m), these rats developed PH (mPAP 32±2 mm Hg). 24 The model has evolved to combine a single, lower dose, subcutaneous injection of SU5416 (20 mg/kg) with 3 weeks of hypoxia (10% oxygen). This reliably generates severe PAH (RVSP 96±11 mm Hg) that persist on return to normoxia. 25 This model develops plexiform arteriopathy that resembles the histology in human PAH; however, it does not lead to RV failure as reliably as the MCT model.
Furthermore, sex and strain differences are important factors to consider when creating the SU5416-hypoxia model. Dean et al 26 showed that metformin reverses development of PH via aromatase inhibition. However, this therapeutic response only occurs in female SU5416-hypoxia rats, suggesting the importance of sex difference in the pathophysiology of PAH. 26 Jiang et al 27 showed marked strain-specific differences in the SU rat model. Surprisingly, ≈75% SpragueDawley rats from Charles River Laboratories (Montreal, QC, Canada) exhibit a severe PAH phenotype with SU5416 (20 mg/kg) subcutaneous injection alone, whereas the other 25% showed no response. 27 In comparison, Sprague-Dawley rats from Harlan Laboratories (Indianapolis, IN) do not develop PAH phenotype with SU5416 (20 mg/kg, SC) alone.
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Models of Group 2 PH
Supracoronary Aortic Banding and Transverse Aortic Constriction Models
The supracoronary aortic banding (SAB) rat or transverse aortic constriction (TAC) mice models are used to study group 2 PH. The SAB model is created by banding the ascending aorta of a juvenile rat, using either a suture or a titanium clip, placed ≈1 cm distal to the aortic valve. [28] [29] [30] Hemodynamic assessment is done 4 to 9 weeks after SAB. [28] [29] [30] Our preliminary data show that 8 weeks after banding and administration of N ω -nitro-l-arginine methyl ester 1.85 mmol/L in drinking water, rats develop marked increase in pulmonary arteriole wall thickness ( Figure 5A and 5B) and decreased PA acceleration time (Figure 5C and 5D; see online-only Data Supplement for the materials and methods section.) In the murine TAC model, a ligature is placed around the aortic arch between the brachiocephalic trunk and left common carotid artery, 11, 31 and hemodynamic assessment is performed 1 to 4 weeks later. 31, 32 In animals that are not in heart failure, tighter aortic banding yields higher trans-banding pressure gradient (TBPG) and LVSP ( Figure 6) ; however, if the aortic banding is too severe, animals die acutely of heart failure. Moreover, if the model progresses to the point of heart failure and cardiac output declines, TBPG will fall in parallel. Although most studies using the SAB model do not report the TBPG, [28] [29] [30] our preliminary data indicate that rise of TBPG is associated with increased RVSP. For example, a TBPG of ≈100 mm Hg generates a RVSP of ≈30 mm Hg 7 to 8 weeks post-banding, with an operative mortality of 5% to 10%. Chen et al 33 used a 26-gauge needle for banding and noted that this produced a mixed group of TAC mice, some with moderate and others with severe heart failure. Subsequently, the same group used a smaller needle (27-gauge) to create more severe TAC and noted that these mice consistently developed severe heart failure. 34 This more severe TAC also caused greater pulmonary inflammatory changes and leukocyte infiltration. 33, 34 These data suggest that a tighter band does indeed create more severe left heart failure and a more severe PH phenotype.
The SAB and TAC rodent models have clinical relevance, mimicking aortic stenosis and aortic coarctation; however, they require technical expertise, develop only modest PH, and do so relatively slowly. The modest PH that develops in SAB and TAC model is similar in magnitude to that seen in patients with isolated LV pressure overload because of diseases such as hypertension. A second, unidentified abnormality, likely some form of endothelial dysfunction, seems to be needed for the generation of severe PH.
Left Atrial Stenosis Model
Fujimoto et al 35 recently generated a novel group 2 PH rat model by partially banding the left atrium with a metal clip in male Sprague-Dawley rat (5 weeks old) to increase the left atrial and pulmonary venous pressure. The left atrial stenosis model, relevant to MS, displayed an increased RV/LV pressure ratio (0.52 versus sham 0.22), increased RV/body weight ratio (0.54 versus sham 0.39 mg/g), and marked medial hypertrophy of the pulmonary veins (1.6× that of sham rats). 35 Immunoblots revealed significantly elevated expression of transforming growth factor-β and ET-1 levels in the lung of the left atrial stenosis versus sham rats. 
Models of Group 3 PH
Chronic Hypoxia Model
Exposing rodents to either normobaric or hypobaric hypoxia generates a group 3 PH model. Rodents are acclimated to decreasing inspired oxygen concentrations over 3 to 5 days and then maintained at 10% oxygen for 3 to 4 weeks. They develop PA medial hypertrophy, elevated mPAP, PVR, and right ventricular hypertrophy (RVH). 22 However, the chronic hypoxia model does not fully recapitulate group 3 PH in humans, which usually results from chronic obstructive pulmonary disease (COPD). 36, 37 Specifically, chronic hypoxia does not cause abnormal lung parenchyma or obstructive PA intimal lesions and induces only mild PH. 36, 37 Both the PH and histological changes reverse when the rodents are returned to normoxia. 22 Many preclinical therapies are effective in preventing and regressing PH in the chronic hypoxic rat model, but most of these have failed to benefit group 3 patients.
Bleomycin-Induced PH
Bleomycin is a chemotherapeutic agent that creates DNA strand breaks. A rodent model of group 3 PH because of pulmonary fibrosis is produced by endotracheal instillation of bleomycin (2-4 U/kg) into rats 38 or mice, 39 respectively. Bleomycin causes fibrogenic cytokine release, resulting in pulmonary fibrosis, increased PA medial thickness, RVH, and PH. 38, 39 In a model using adult male C57/BL6 mice, survival is 74% 2 weeks post-bleomycin. 39 Male Wistar rats instilled with bleomycin developed significant pulmonary fibrosis, accompanied by increased lung expression of hydroxproline, collagen, and connective tissue growth factor.
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Model of Group 4 PH
A group 4 PH model has recently been created by tail vein injection of male Sprague-Dawley rats with 85 μm polystyrene microspheres plus subcutaneous SU5416 (20 mg/ kg). 40 All rats treated with microspheres+SU5416 developed sustained PH (RVSP of 62±13 and 53±14 mm Hg at 3 and 6 weeks, respectively). They also developed significant RV dysfunction, RVH, and RV fibrosis and had decreased exercise capacity. Lung sections of the microspheres+SU5416 rats demonstrated marked medial hypertrophy in small arterioles and intimal proliferation with obliteration of the lumen; however, as in humans with group 4 disease, there were no plexiform lesions. Computed tomography pulmonary vascular imaging showed lack of neovascularization, and Ki-67 immunohistochemistry showed decreased cellular proliferation in the microspheres+SU5416 group versus either microspheres or sham group. The microspheres+SU5416 rats also had evidence of increased inflammation and platelet activation. 40 In contrast, with microspheres alone, only 10% of rats developed PH. Hence, a combined insult (pulmonary embolism plus inhibition of endothelial function) is required to routinely induce group 4 PH.
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WHO Group 2 to 4 PH in Patients
We will next discuss the definitions and disordered molecular pathways associated with group 2 to 4 PH in patients.
WHO Group 2 PH
PH-LHD is defined as a mPAP ≥25 mm Hg with elevated left heart filling pressures (PCWP >15 mm Hg or left ventricle enddiastolic pressure >18 mm Hg). 41 PH-LHD is subclassified as isolated postcapillary PH or combined post-and precapillary PH. In isolated postcapillary PH, the diastolic pulmonary vascular gradient, defined as PAP diastolic -PCWP, is <7 mm Hg and the PVR≤3 WU, whereas in combined post-and precapillary PH, the diastolic pulmonary vascular gradient is ≥7 mm Hg and the PVR>3 WU. 42 The major causes of elevated left heart filling pressures and heart failure that give rise to PH are (1) mitral and aortic valvular disease and (2) LV myocardial diseases. Heart failure is further subdivided into heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). 41 ( Figure 7 ) Most patients with HFrEF or HFpEF develop PH. A community-based study showed that 83% of HFpEF patients (n=244; mean age 76±13 years; 45% male) have PH. 43 The incidence of PH in HFrEF patients is similar (72%-79%). 44, 45 The treatment of group 2 PH focuses on symptomatic care (diuretics, sodium restriction) and correction of the underlying LHD. For HFpEF, this often involves control of systemic hypertension to a target pressure of 120/80 mm Hg. For HFrEF, this involves the use of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, as well as β-adrenergic receptor antagonists. For patients with valvular LHD, surgical correction of the valve abnormality is recommended. However, group 2 PH cannot always be completely reversed by treating the LHD, 16 as discussed previously ( Figure 2 ). We next review molecular mechanisms that may be responsible for the pathological remodeling and vasoconstriction of the pulmonary vasculature that underlies disproportionate PH in some group 2 patients (Table 1) .
Disordered Pathways in Group 2 PH
Endothelial Dysfunction PH-LHD is associated with endothelial dysfunction, characterized by an increase in levels of vasoconstrictors, such as ET-1 and a decrease in vasodilators, such as NO 50, 51 ( Figure 8 ). Pathophysiology of group 2 pulmonary hypertension (PH). In most patients, left heart disease increases pulmonary venous pressure and causes a proportionate PH (left). However, for unknown reasons, in a minority of patients with left heart disease, elevation of pulmonary venous pressure leads to adverse pulmonary vascular remodeling, and pulmonary vasoconstriction. This causes disproportionate PH, which may not fully resolve with relief of elevated pulmonary venous pressure. HFpEF indicates heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction.
Endothelin-1
ET-1 is a potent vasoconstrictor identified by Yanagisawa in 1988. 52 ET-1 levels are markedly elevated in PH, including group 2 patients. 53 Exposing endothelial cells to increased pressure increases ET-1 production by a phospholipase C and PKC (protein kinase C)-dependent mechanism. 54 Pressureinduced elevations of ET-1 likely contribute to group 2 PH.
ET-1 binds to ET A and ET B receptors. 55 ET A receptors are expressed mainly on vascular smooth muscle cells (VSMCs) and cardiac myocytes. Binding of ET-1 to ET A receptors activates phospholipase C, which generates diacylglycerol and inositol triphosphate (IP 3 ). 56 These secondary messengers trigger the release of intracellular calcium, which leads to activation of myosin light chain kinase, phosphorylation of myosin light chain, and vasoconstriction. 56 ET-1 also activates the RhoA/ROCK (Rho kinase) pathway, which leads to calcium sensitization and sustained vasoconstriction. 57 ET B receptors are expressed on vascular endothelial cells and, on binding of ET-1, promote production of NO and prostacyclin, resulting in vasodilation. 58 The ratio of ET A to ET B receptors in humans is ≈9:1, and the net effect of ET-1 on pulmonary arteries is vasoconstriction. 59 In heart failure, there is not only elevation of ET-1 levels but also increased vasoconstrictor responsiveness to ET-1. 60 In a canine HF model induced by rapid ventricular pacing, Tadano et al 46 demonstrated a functional shift of ET receptor subtypes favoring vasoconstriction. Although there is biological plausibility that ETRAs (endothelin receptor antagonists), such as bosentan or macitentan, might benefit PH-LHD patients, many clinical trials indicate a lack of benefit. [61] [62] [63] [64] In examining putative PH-targeted therapies, one must not only consider their pulmonary vascular interactome but also their effect on the RV, which is a key determinant of prognosis in ] I indicates intracellular calcium concentration; cGMP, cyclic guanosine monophosphate; CHF, congestive heart failure; EF, ejective fraction; EGFR, endothelin growth factor receptor; eNOS, endothelial nitric oxide synthase; ET, endothelin; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; LV, left ventricle; LVEDP, left ventricle end-diastolic pressure; mPAP, mean pulmonary arterial pressure; NE, norepinephrine; NO, nitric oxide; PA, pulmonary artery; PAWP, pulmonary artery wedge pressure; PDE5, phosphodiesterase 5; PH, pulmonary hypertension; RVSP, right ventricle systolic pressure; RVH, right ventricle hypertrophy; SAB, supracoronary aortic banding; sGC, soluble guanylate cyclase; and TAC, transverse aortic constriction.
PH. One potential mechanism for the lack of benefit from ETRA in group 2 PH is the preclinical observation that some ETRAs are negative RV inotropea.
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NO-Soluble Guanylate Cyclase-Cyclic GMP Pathway NO is an endothelium-derived vasodilator produced from l-arginine by the endothelial NO synthase (eNOS). 66 NO is a nitrogen-based radical and has a short half-life of only 0.05 to 1 second. 67 NO is synthesized in the endothelium and diffuses to subjacent smooth muscle cell (SMC). 68 The effects of this gaseous vasodilator are largely exerted by activation of its molecular receptor, soluble guanylate cyclase (sGC), and subsequent generation of cyclic GMP. 19 NO production can be triggered by various endogenous factors, such as acetylcholine and bradykinin, or mechanical stimuli, such as shear stress and stretch. [69] [70] [71] sGC stimulators, such as riociguat, compensate for deficiency in biologically active NO and for sGC dysfunction, resulting from sGC oxidation or loss of sGC's heme moiety. 72 Riociguat is approved for treatment of group 1 and group 4 PH. 73 However, in the LEPHT trial (Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial), which studied 201 group 2 patients, riociguat (2 mg 3× daily for 16 weeks) failed to reduce mPAP, the study's primary end point. 74 Riociguat did improve cardiac index and reduced PVR and systemic vascular resistance. 74 Both decreased NO production and reduced vasodilator responsiveness to NO occur in PH-LHD. 75 SAB rats have impaired pulmonary endothelium-dependent vasodilation and reduced lung capillary endothelial NO synthesis. 47 The impaired NO synthesis reflects a decrease in intracellular calcium oscillations in endothelial cells, rather than downregulation of eNOS. 47 Calcium oscillations were attenuated in SAB rats in response to mechanical stress, acetylcholine, histamine, and thapsigargin, an inhibitor of sarcoplasmic reticulum Ca
2+
ATPase. 47 The Ca 2+ ionophore, A-23187 restored endothelial calcium oscillations and NO production. 47 Thus, the underlying cause of endothelial dysfunction and decreased NO production in this preclinical group 2 PH model is dysfunction of endothelial calcium signaling pathways. The cause of impaired calcium signaling in group 2 PH and its relevance to human PH requires further study.
The endothelium has many functions beyond NO synthesis. Simply eliminating NO by exposing rats to N ω -nitro-larginine methyl ester (1.85 mmol/L in drinking water for 3 weeks) failed to cause group 2 PH, despite induction of severe systemic hypertension.
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Phosphodiesterase 5 Dysregulation
Phosphodiesterase 5 (PDE5) catalyzes the hydrolysis of cyclic GMP. Although PDE5 inhibitors, such as sildenafil, are approved therapy for group 1 PH, off-label use of sildenafil in group 2 PH patients shows some potential clinical and hemodynamic benefits. 77, 78 In the SAB rat model, sildenafil (60 mg/kg daily for 8 weeks) decreased endothelial dysfunction ( Figure 9A ), restored NO production ( Figure 9B ), and restored pulmonary arteriole vasorelaxation ( Figure 9C) . 29 Interestingly, the PDE5 expression in SAB rat lung homogenate was decreased by ≈50%. 29 This differs from group 1 PH rat models in which lung PDE5 expression is increased. 79, 80 Nonetheless, plasma cyclic GMP levels were reduced in SAB rats, and sildenafil significantly increased cyclic GMP levels. 29 Clinical trials of sildenafil in group 2 PH are promising. A review by Hansdottir et al 81 summarized 3 small trials showing patients with PH secondary to HFrEF and HFpEF treated with sildenafil (25-75 mg orally 2-3 times daily for 12 weeks to 1 year) had reduced hospitalizations for HF, improved exercise capacity, enhanced quality of life, reduced mPAP, and decreased breathlessness score versus control subjects. 81 Two multicenter clinical trials testing PDE5 inhibitors in group 2 PH are currently underway (PITCH-HF trial for tadalafil [Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure]; NCT01910389 and the Sil-HF trial 82 for sildenafil [Sildenafil in Heart Failure]; NCT01616381).
Mitochondrial Dysfunction
Mitochondria are not only generators of ATP but also regulate processes such as cell proliferation and apoptosis. 83 Mitochondria have noncanonical function that in aggregate are referred to as mitochondrial dynamics. 83 These properties include division (fission), union (fusion), movement (translocation), biogenesis, and quality control (mitophagy). Using confocal imaging, and mitochondrial-targeted potentiometric dyes and fluorescent probes, one can visualize dynamic networks of mitochondria in live cells. 83 Acquired disorders of mitochondrial metabolism and dynamics contribute to the pathogenesis of complex diseases, such as cardiovascular disease, neurodegenerative disease, and cancer. 84 In group 1 PH, there are acquired abnormalities of mitochondrial metabolism and dynamics 83 in both the pulmonary vasculature 85 and RV. 86 The mitochondrial phenotype in PAH includes suppression of glucose oxidation, because of increased expression and activation of pyruvate dehydrogenase kinase (PDK), 83, 86, 87 and mitochondrial fragmentation, because of increased mitochondrial fission and impaired mitochondrial fusion. 88 The metabolism of glucose normally involves close coupling of cytosolic glycolysis with mitochondrial glucose oxidation (which relies on the pyruvate generated by glycolysis). However, PDK activation can disrupt this coupling by phosphorylating and inhibiting pyruvate dehydrogenase. 87 This Figure 8 . Imbalance in endothelin-1 (ET-1) and nitric oxide (NO) homeostasis in pulmonary hypertension favors pulmonary vasoconstriction.
metabolic shift (called the Warburg phenomenon) is reversed by PDK inhibitors, such as dichloroacetate, with therapeutic benefit to the pulmonary vasculature and RV. 87, 89, 90 Uncoupled glycolysis promotes cell proliferation and suppresses mitochondria-mediated apoptosis. 87 This favors survival of abnormal cells in the pulmonary circulation and impairs the bioenergetic reserve of the RV. In models of group 1 PH, such as the fawn-hooded rat (a group 1 PH model caused by epigenetic silencing of superoxide dismutase 2, SOD2) and MCT rats, PDK inhibition regresses established pulmonary vascular disease. 89, 90 In the PAH RV, the metabolic shift to Warburg metabolism causes RV hypokinesis, and this too is improved by dichloroacetate. 86, 87 Although there are parallels in the metabolic alterations in the pulmonary arterial smooth muscle cell (PASMC) and RV cardiomyocytes, the initiating factors and their functional consequences differ. In PASMC, the mitochondrial morphological changes reflect enhanced mitotic fission, which is initiated by the kinases that regulate both the activation of the fission mediator, Drp1 (dynamin-related protein 1) and mitosis 85 (eg, cyclin B-CDK1), as well as by elevation of cytosolic calcium. 88 The consequences of the mitochondrial metabolic phenotype in the vasculature is accelerated cell proliferation and migration and apoptosis resistance. 83 In the RV myocytes, changes in metabolism and dynamics are likely initiated by RV ischemia and result in myocardial hibernation and reduced RV function. 86 Cell division requires a coordination of nuclear and mitochondria division. 83 Mitochondrial fission that is coordinated with mitosis is called mitotic fission. The coordination reflects a shared reliance on mitosis promoting Drp1-activating kinases, including cyclin B1-CDK1. 83 Mitochondria in PAH PASMC are fragmented because of increased fission (caused by activation of Drp1) and impaired fusion (caused by decreased function of the fusion mediator, mitofusion-2). 87 This fission/fusion imbalance promotes excessive cell proliferation and impairs apoptosis. 83 Preventing mitotic fission, by inhibiting Drp1 or enhancing mitofusin-2, causes cell cycle arrest and can regress vascular disease and improve hemodynamics in experimental models of PAH. 83 In PAH, RV ischemia, related to microvascular rarefaction and impaired coronary perfusion pressure, promotes Drp1 activation and mitochondrial fission, which increases reactive oxygen species (ROS) production. 83 Inhibiting fission, using the Drp1 inhibitor, mitochondrial division inhibitor-1, Mdivi-1, or P110 (a competitive peptide inhibitor of the interaction between Drp1 and its binding partner, Fis1 [fission protein 1]), preserves RV function in an ischemia-reperfusion injury model. 91 Interaction between the changes in metabolism and altered mitochondrial dynamics in PH is poorly understood. In group 1 PH, impaired expression and function of the mitochondrial calcium uniporter complex (MCUC) constitutes one link between metabolism and dynamics. 88 The MCUC is the major route of calcium entry into the mitochondrial matrix. 88 Loss of MCUC function (because of a downregulation of the pore forming subunit, called MCU, and upregulation of the negative regulatory element MICU1) impairs mitochondrial calcium uptake and causes accumulation of calcium in the cytosol. 88 Reduced intramitochondrial calcium inhibits calcium-sensitive dehydrogenases within the mitochondria, including pyruvate dehydrogenase. This inactivates Krebs' cycle, contributing to the shift to uncoupled glycolysis. 88 The elevation of cytosolic calcium, resulting from impaired MCUC function, promotes vasoconstriction and mitochondrial fission. 88 The downregulation of MCUC in PAH results from increased expression of microRNAs (miRs) miR-138 and miR-25. Anti-miRs against these epigenetic mediators reduces PASMC proliferation, migration, and apoptosis resistance and regress experimental PAH. 88 The potential role of the MCUC in group 2 PH has not been assessed.
Data regarding mitochondria in PH-LHD is scarce. In dogs with congestive heart failure produced by intracoronary microembolizations, the number of mitochondria in cardiomyocytes was increased, but their average size was smaller, both in the LV and RV. 48 These findings are consistent with increased fission. Although RVSP or mPAP was not reported, mean left ventricle end-diastolic pressure (23±3 mm Hg) and pulmonary artery wedge pressure (13±1 mm Hg) were markedly elevated compared with those of control. Dogs with the highest plasma norepinephrine (>600 pg/mL) had smaller mitochondria and worse heart failure. 48 In the TAC model, Mdivi-1 improves LV function and prevents ventricular remodeling by preventing cardiomyocyte apoptosis and promoting angiogenesis. 12 Inhibiting mitochondrial fission also preserves LV function in a global ischemia model and, in a rodent cardiac arrest model, enhances the success of resuscitation. 92, 93 However, the pulmonary hemodynamics were not reported in these studies. Thus, it is uncertain whether inhibiting mitochondria fission in group 2 PH can improve RV function or clinical outcomes.
RhoA/ROCK Pathway
The RhoA/ROCK pathway is implicated in PH-LHD. 28, 30 ROCK is a serine/threonine kinase that is activated when it binds GTP-bound RhoA. 94 RhoA, a small GTPase, is activated by GEF (guanine nucleotide exchange factor) and inactivated by GAP (GTPase-activating protein). 94 Normally, a balance between GEF and GAP determine RhoA activity, which regulates the 2 ROCK isoforms. 95 ROCK1 is expressed in circulating inflammatory cells, whereas ROCK 2 (Rho kinase 2) is found in VSMC. 96, 97 The ROCKs produce sustained vasoconstriction because of calcium sensitization, a result of their interactions with substrates, including myosin light chain and myosin phosphatase target subunit-1. 98 Relevant to PH, ROCK activation also increases VSMC proliferation, inflammatory cell migration, platelet activation, ROS production, and endothelial dysfunction. 98 Myosin phosphatase target subunit-1 is activated in the lungs of rats with SU5416-hypoxia-induced PAH, and this is reversed by the ROCK inhibitor, fasudil. 99 ROCK inhibition regresses SU5416-hypoxia-induced PAH, suggesting that severe sustained vasoconstriction is important. 99 RhoA/ROCK inhibition also attenuate PH-LHD induced by SAB. 28, 30 Fasudil (30 mg/kg per day administered from day 29 to 42 post-banding) decreased mPAP by 65%, RVH by 30%, and PA medial thickness by 50%. 28 On a molecular level, fasudil decreased expression of ROCK2 by 28% (without altering ROCK1) while increasing lung eNOS. 28 Drugs that indirectly inhibit the RhoA/ROCK pathway also attenuate PH-LHD in rodent models. Atorvastatin (10 mg/kg/day orally for 9 weeks), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, 30 significantly reduced RhoA and ROCK2 expression in SAB rats by impairing production of isoprenoids, which are required for isoprenylation of ROCK. 30 However, this same statin failed to regress group 1 PH in both rats and humans.
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Metabolic Syndrome
Metabolic syndrome has emerged as a risk factor for both group 1 102, 103 and group 2 PH. 104 In mice, there is a link between genetic background and susceptibility to PH induced by a high-fat diet. In a genome-wide association study of 36 mouse strains challenged with 20 weeks of high-fat diet, 105 variants in the endothelial growth factor receptor gene were associated with increased susceptibility to group 2 PH. 49 Endothelial growth factor receptor expression was increased in the lungs of mice with the most severe high-fat diet PH (although the severity of PH in this study was mild). 49 Previous studies have identified the critical role of endothelial growth factor receptor in PASMC growth, vascular remodeling, and survival in experimental model of group 1 PH. 106 Based on the genomewide association study and supporting data, Kelly et al 49 concluded that higher baseline level of endothelial growth factor receptor expression may increase susceptibility to high-fat diet-induced group 2 PH. Type 2 diabetes mellitus is a component of metabolic syndrome. Chronic hyperglycemia inhibits AMPK (adenosine monophosphate-activated protein kinase). 107 AMPK is a heterotrimeric enzyme with α, β, and γ subunits. AMPK serves as a fuel gauge, generating ATP as required to correct energy depletion. When AMP levels are increased, AMPK is activated. There are 12 AMPK variants with tissue-specific distribution. 108 AMPK is activated by phosphorylation of its α-subunit at threonine 172. This phosphorylation is regulated by competitive binding of AMP versus ATP to the γ subunit. 108 Metformin, which is used to treat type 2 diabetes mellitus, is an AMPK activator. 109 In experimental group 2 PH, metformin decreases RVSP and adverse vascular remodeling. 110 Lai et al 110 developed a model of metabolic syndrome and PH-HFpEF by injecting an obese rat strain (obese ZSF1) with SU5416. In this model, metformin decreased hyperglycemia, activated AMPK in PASMC, and caused beneficial vascular remodeling. Metformin 111 and a more selective AMPK activator, 5′-aminoimidazole-4-arboxamide ribonucleoside, 112 also decrease PASMC proliferation and improve survival in rodent PAH models.
Lung Inflammation and Fibrosis
Chen et al 33 showed that male TAC mice (C57B6J) have a ≤5.3-fold increase in lung wet weight that reflects massive pulmonary fibrosis and significant pulmonary leukocyte infiltration, rather than pulmonary edema. Thus, lung fibrosis and inflammation may play an important role in the pathophysiology of group 2 PH. 33 Wang et al 34 used either CD28 or B7 knockout mice, which have impaired T-lymphocyte activation to show that activated effector T cells (CD3 + CD44 high cells) play a central role in the inflammatory response associated with TAC-induced HF. Knockout mice lacking either CD28 or B7 had dramatic reduction in the accumulation of activated effector T cells in both the heart and the lung and had better preserved LV function post-TAC. Although RVSP was not measured in this study, the ratio of RV/body weight was significantly reduce in both the CD28 or B7 knockout TAC mice 34 These data suggest targeting T cell activation may be useful in treating group 2 PH.
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WHO Group 3 PH
Group 3 PH is defined as mPAP ≥25 mm Hg, and PCWP pressure ≤15 mm Hg is associated with COPD, interstitial lung disease, sleep disordered breathing, alveolar hypoventilation disorders, or chronic exposure to high altitude. 113 RV failure associated with group 3 PH is referred to as "cor pulmonale." Group 3 patients may receive long-term supplemental oxygen and supportive care with diuretics; however, PH-targeted therapies are not recommended. 42, 113 The nonselective nature of the vasodilatation caused by these agents often impairs hypoxic pulmonary vasoconstriction and exacerbates hypoxemia. For example, when group 3 patients (mPAP >30 mm Hg) with COPD exacerbations requiring mechanical ventilation were randomized to receive flolan (prostacyclin, 2-12 ng/kg/min, intravenously) versus placebo, PVR was reduced, but there was no improvement in respiratory status. 120 Patients receiving flolan developed more severe hypoxemia because of the nonselective vasodilatation. Likewise, ETRAs are not recommended for group 3 PH. 121, 122 Although small openlabel studies suggest that PDE5 inhibitors, 123, 124 sGC stimulators, 125 and intravenous prostacyclins 126 may be beneficial in selected group 3 patients, larger, double-blinded trials would be required to change practice. We next review disordered molecular pathways in group 3 PH (Table 2) .
Disordered Pathways in Group 3 PH
Endothelial AMPK AMPK is a putative therapeutic target in PH. 26, 114 Dean et al 26 showed that metformin can reduce the development of PH in the SU5416/hypoxia female rat model. While this is considered a group 1 model, there is some relevance to group 3 PH, in that hypoxia is a key contributor to the model. Metformin's mechanism of action is complex. They propose that the metformin activates AMPK, which in turn inhibits aromatase. 26 Aromatase converts testosterone to estrogen, which in turn is metabolized via cytochrome p450 1B1 to generate 16a-hydroxyestrone, a metabolite known to cause PH. 26 Interestingly, inhibiting aromatase activity is only effective in the female PH rat models. 26 Epidemiological studies reveal that a higher percentage of female than male COPD patients have PH. 127, 128 Thus, both in humans and in rodent models, there are important sex difference in the pathophysiology of group 3 PH.
In addition to responding to bioenergetic perturbations, AMPK can be activated by inhibition of ROCK. 129 AMPK activation has differential effects in endothelial versus SMC. In endothelial cells, AMPK activates eNOS and has an antiapoptotic effect, whereas in VSMCs, it reduces secretion of various growth factors and has a proapoptotic effect.
130-132
Omura et al 114 showed that AMPK is downregulated in a hypoxia-induced group 3 PH mouse model. Moreover, they created eAMPK −/− (endothelial-specific AMPK knockout mice). 114 The eAMPK −/− mice have no basal increase in percent muscularized distal PA; however, compared with control mice, they develop more severe PH after 4 weeks of hypoxia. 114 The eAMPK −/− mice have impaired endothelial function (because of reduced eNOS activity) and increased PASMC proliferation because of upregulation of growth factors (PDGF-BB [platelet-derived growth factor-BB] and FGF-2 [fibroblast growth factor-2]). 114 Metformin, attenuates hypoxia-induced PH in these mice. 114 Li et al 133 showed that AMPK activation in endothelial cells prevents Drp1-mediated mitochondrial fission and improves endothelial function. Pretreating rat aortic endothelial cells with AMPK activators, salicylate or 5′-aminoimidazole-4-arboxamide ribonucleoside, prevents palmitate-induced mitochondrial fission, with an efficacy that is comparable to Mdivi-1. 133 This study suggests that endothelial AMPK activation inhibits Drp1 recruitment, prevents mitochondrial fission, and provides an intriguing link between the disorders of mitochondrial dynamics and bioenergetics that may be relevant to group 3 PH. However, metformin has many actions in addition to AMPK activation, including an anti-inflammatory effect evident in its ability to inhibit of endoplasmic reticulum stress-associated inflammasome activation in the adipose tissue of diabetic mice. 134 However, there are also data suggesting AMPK activation may be harmful in group 3 PH. Ibe et al 135 showed that inhibition of AMPK with compound C significantly reduced RVH, RVSP, and pulmonary vascular remodeling in chronically hypoxic C57BL/6 mice. The opposing data on the role of AMPK inhibition may reflect the different animal models used, off-target effects of AMPK modulating drugs, the cellular compartment in which the AMPK dysregulation occurs (SMC versus endothelium), and tissue heterogeneity in AMPK isoform expression.
RhoA/ROCK Pathway
Hemnes et al 39 showed that sildenafil inhibits ROS generation and RhoA/ROCK activation, thereby, attenuating bleomycininduced PH. Male C57/BL6 mice were treated with intratracheal bleomycin (4 U/kg). 39 Sildenafil (100 mg/kg/day orally) improved survival by 10.5%, reduced RVH and fibrosis, and pulmonary vascular medial hypertrophy. 39 PDE5 inhibition decreased RhoA and ROCK activity, increased PKG activity, enhanced eNOS activity, and inhibited inducible NO synthase. 39 Hypoxia-induced PH is attenuated in heterozygous ROCK2 +/− (ROCK2-deficient) mice and exacerbated in VSMC-specific ROCK2-Tg (ROCK2-overexpressing transgenic mice). 97 ROCK activity exacerbates PH by increasing cell proliferation. In ROCK2 +/− mice, both the expression of the activated form of the mitosis-promoting kinase ERK1/2 (extracellular signal-regulated kinase) and the number of Ki67-positive proliferating cells in the lung were reduced, whereas in the ROCK2-Tg mice, opposite results were found. 97 
Hypoxia-Inducible Factor
The transcription factor, HIF-1α (hypoxia-inducible factor), plays an important role in the pathogenesis of PAH. 90 Patients with group 3 PH are exposed to chronic hypoxia either secondary to diseased lung parenchyma (COPD), intermittent apnea (sleep apnea), or environmental hypoxia (altitude). Thus, HIF-1α also plays a key role in the pathogenesis of group 3 PH. 136 HIF-1α is activated in the rodent hypoxia PH model. 6 HIF-1α haploinsufficiency protects mice from group 3 PH, reducing polycythemia, RVH, mPAP, and adverse pulmonary vascular remodeling.
In chronic hypoxia, HIF-1α-dependent transcriptional activation of the TRPC1 (transient receptor potential channel 1) and NHE1 (sodium-hydrogen antiporter 1) genes increases intracellular calcium concentration ([Ca 2+ ] i ) and intracellular pH (pH i ) in PASMC, respectively. 115, 116 Inhibiting HIF-1α, using digoxin, decreases [Ca 2+ ] i and pH i , reduces RVH, and attenuates pulmonary vascular remodeling in this model (Figure 10 ). ] I , intracellular calcium concentration; CyPA, cyclophilin A; DCA, dichloroacetate; eAMPK, endothelial AMPK; eNOS, endothelial nitric oxide kinase; ERK1/2, extracellular signal-regulated kinase 1 and 2; FGF-2, fibroblast growth factor-2; FHR, fawn-hooded rats; HIF, hypoxia inducible factor; iNOS, inducible nitric oxide kinase; IP, intraperitoneal; Kv, voltage-gated potassium channel; NHE1, sodium-hydrogen antiporter 1; PASMC, pulmonary arterial smooth muscle cell; PDGF-BB, platelet-derived growth factor-BB; PDE5, phosphodiesterase 5; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PH, pulmonary hypertension; pH i , intracellular pH; PKG, cGMP-dependent protein kinase; ROCK, Rho-associated protein kinase; ROS, reactive oxygen species; RV, right ventricle; RVH, right ventricular hypertrophy; TRPC1, transient receptor potential channel 1; and VEGF, vascular endothelial growth factor.
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HIF-1α also regulates the expression of voltage-gated, oxygen-sensitive potassium channels. 90 Normoxic activation of HIF-1α in fawn-hooded rat inhibits the expression of Kv1.5. This depolarizes PASMC, which activates the voltage-dependent, large conductance calcium channel and elevates [Ca 2+ ] i .
Conversely, augmenting SOD2 inhibits HIF-1α, restores Kv1.5 expression, and regresses PH. 90 Consistent with this, Whitman et al 137 found that Kv1.5 and Kv2.1 expression is preserved in HIF-1α haploinsufficient mice exposed to chronic hypoxia. These ionic mechanisms are relevant both for control of pulmonary vascular tone and structural remodeling. 
Mitochondria-ROS-HIF-1α-Kv Channel Pathway
Hypoxia stabilizes HIF-1α, increasing its accumulation in the nucleus and its activity. The regulation of HIF-1α involves oxygen-sensitive prolyl hydroxylases and von Hippel-Lindau factor-mediated ubiquitination. 138 However, the cell's redox state, which is largely determined by mitochondria, also regulates HIF-1α.
6 SOD2 converts toxic, short-lived ROS, produced by the mitochondrial electron transport chain, into diffusible H 2 O 2 , a redox-signaling molecule that regulates HIF-1α. 6 Mitochondrial ROS can be regulated by PO 2 or by alteration in SOD2 expression. Hypoxia alters mitochondrial ROS production. 119, 139, 140 Controversy exists as to whether hypoxia increases or decrease mitochondrial ROS production. However, we consistently find that ROS production in whole lungs, PASMC, and PASMC mitochondria decreases in response to physiological hypoxia. In FHR PASMC, a deficiency in normoxic H 2 O 2 production, triggered by epigenetic SOD2 downregulation, creates a pseudo hypoxic milieu, in which normoxic activation of HIF-1α promotes PH. 90 HIF-1α activation increases transcription of PDK, which creates a pathological metabolic shift from oxidative glucose metabolism to reliance on uncoupled glycolytic metabolism. This form of metabolism is also observed in cancer and is called the Warburg effect. 6, 87 Hence, there is biological plausibility that drugs that modulate mitochondrial metabolism may have therapeutic potential in group 1 and group 3 PH. Michelakis et al 118 showed that dichloroacetate, a metabolic modulator that inhibits all 4 isoforms of PDK, regresses chronic hypoxic PH in rats (Figure 11 ). PDK inhibition increases glucose oxidation and mitochondrial NADH (nicotinamide adenine dinucleotide), thereby, increasing mitochondrial electron flux and restoring physiological ROS production. Dichloroacetate also regresses PH in the FHR model.
90
Cyclophilin A-Basigin Pathway
Basigin (Bsg), also known as CD147 or extracellular matrix metalloproteinase inducer, is a ubiquitous transmembrane glycoprotein. 14, 32 Bsg is activated by cyclophilin A (CyPA; an immunophilin), mechanical stretch, soluble Bsg, or angiotensin II. 14, 32 Bsg regulates many intracellular pathways involved in VSMC proliferation, including matrix metalloproteinase activation, autophagy, and platelet activation. 14, 32 Haploinsufficiency of CyPA (CyPA +/− ) or Bsg +/− reduces chronic hypoxic PH and PA remodeling in mice. 14 Furthermore, Bsg +/− PASMC had reduced rates of proliferation.
14 CyPA +/− mice exposed to hypoxia had lower levels of inflammatory cytokines, especially chemokine ligand 2, macrophage colony-stimulating factor, IL (interleukin)-2, and IL18.
14 Proliferative signaling was also reduced in PASMC from hypoxic Bsg +/− mice, with reduced expression of PDGF-BB and decreased phosphorylation of ERK1/2. 14 These data suggest that CyPA/Bsg signaling regulates inflammatory cell recruitment and growth factor secretion and may be a novel therapeutic target for treating group 3 PH. In PAH patients, plasma CyPA levels directly correlate with PVR.
14
WHO Group 4 PH (CTEPH)
CTEPH occurs when pulmonary emboli fail to resolve and an obstructive neointima reduces perfusion to a critical volume of the pulmonary circulation. 141 The incidence of CTEPH after acute pulmonary embolism ranges from 0.1% to 9.1% (average 4%). 9, [147] [148] [149] [150] [151] [152] A clinically diagnosed pulmonary embolic event is absent in one third of CTEPH patients. 141 Once established CTEPH gradually worsens, even without additional clinical embolic events. 141 The preferred treatment is pulmonary thromboendarterectomy (PTE). 141 In the United States, the estimated annual incidence of CTEPH is around 5000 cases, but only 300 to 400 PTEs/year are performed, suggesting patients are being deprived of an effective therapy. 141 In 2013, riociguat, a sGC stimulator, was approved for inoperable CTEPH patients. 73 In CHEST-2 (Long-Term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension), riociguat improved 6-minute walk test duration and reduced PVR and N-terminal pro-brain natriuretic peptide in PTE-ineligible patients. 73, 153 We next review disordered molecular pathways in group 4 PH (Table 3) .
Disordered Pathways in Group 4 PH
Endothelial Dysfunction
In creating a novel CTEPH animal model, Neto-Neves et al 40 showed embolization with polystyrene microspheres alone was usually insufficient to create CTEPH. However, combining embolization with SU5416 reliably produced sustained PH (Figure 12) . 40 Likewise, plasma levels of asymmetrical dimethylarginine, a potent endogenous NOS inhibitor, are significantly elevated in CTEPH patients, and eNOS expression is reduced. 142 Thus, there is an important synergistic, role of endothelial dysfunction in promoting CTEPH in polystyrene microspheres patients.
ET-1
ET-1 levels are increased in dogs with CTEPH (induced by repeated embolization with ceramic beads). 141 Bosentan attenuated pulmonary vascular remodeling and reduced mPAP and PVR in this model. 143 Reesink et al 144 found serum ET-1 levels were increased in 35 CTEPH patients (1.62±0.21 pg/mL) compared with controls (0.75±0.06 pg/mL). Furthermore, ET-1 levels correlated well with measures of CTEPH severity, including mPAP (r=0.70), cardiac index (r=−0.76), total pulmonary resistance (r=0.72), and 6-minute walk test (r=0.59). ET-1 levels >1.77 pg/mL are associated with a bad • Optimal preclinical models that recapitulate many forms of group 2 PH (eg, mitral stenosis), group 3 PH (eg, obstructive sleep apnea), and group 4 PH do not exist or are not well standardized and easy to use.
• Preclinical therapeutic trials require greater rigour in terms of duration, end points, and characterization of cardiopulmonary function and structure. Optimal assessment of PH should include characterization of the pulmonary vasculature and right ventricle and careful measurement of diastolic function of the left ventricle. This requires advanced hemodynamic studies in closed-chest animals. Broader application of high-fidelity ultrasound, cardiac catheterization, micro-CT, positron emission tomography, and MRI is required to better phenotype groups 2-4 PH and measure response to experimental therapeutics.
• The importance of age, sex, diet, and strain differences on hemodynamics, lung and heart histology, and mortality in preclinical models of group 2-4 PH is poorly understood.
• The mechanism by which disproportional PH develops in groups 2 and 3 patients is not well understood. It is unclear, for example, why similar elevations of LVEDP or LA pressure elicits severe PH in some patients and experimental animals while only eliciting a modest increase in PVR in others.
• Can disordered molecular pathways that are shared by several PH groups be therapeutically exploited to create more universally applicable PH-targeted therapies?
• The importance of changes in mitochondrial metabolism and mitochondrial dynamics in Group 2-4 PH is unknown.
• The role of genetic and epigenetic dysregulation in group 2-4 PH is largely unknown.
• It is poorly understood why a second insult, in addition to aortic banding, hypoxia, and pulmonary embolism, is often needed to generate severe PH in preclinical models. The role of adverse stimuli, such as endothelial dysfunction, inflammation, impaired angiogenesis, or metabolic syndrome, in the genesis of group 4 PH patients remains poorly characterized. These PH-promoting abnormalities are not factored into the WHO classification system nor are they included in the standard operating procedures for creation of most preclinical PH models.
• The prevalence and prognostic impact of adaptive versus maladaptive right ventricular responses to group 2-4 PH is poorly understood.
• Most preclinical studies of PH mechanisms focus on a single molecular pathway. A systems biology approach that addresses the interaction of pathways is needed.
• Therapies for group 1 PH are ineffective in groups 2-3 PH and the optimal molecular targets for groups 2-4 PH remain poorly defined. Therefore, better understanding of the basic mechanisms underlying each of these PH groups is required to identify new therapeutic targets. This will require integrated use of preclinical models and human cells. The value of blood out growth endothelial cells (BOECs) as readily accessible, disease-relevant cells remains unknown.
• The potential value of modifying the current PH classification system based on better understanding of molecular mechanisms is unexplored. Could knowledge of pathological mutations, epigenetic modifications, and altered signaling pathway function refine the WHO classification system to better support a more personalized medicine approach to diagnosis and treatment?
LA indicates left atrium; LVEDP, left ventricle end diastolic pressure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; and WHO, World Health Organization. Hypertension), patients with inoperable CTEPH were randomized to placebo (80) ) but did not improve 6-minute walk distance (+2.2 m) or reduce mPAP (−2.5 mm Hg). 155 In MERIT-1 (Macitentan for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension; NCT02021292), a randomized, double-blind, placebo-controlled study, macitentan (10 mg/daily for 24 weeks) significantly improved PVR and 6-minute walk distance in CTEPH patients. 156 However, the validity of the unpublished data awaits peer review.
Platelets in CTEPH
Surprisingly, the prevalence of hereditary thrombophilia, such as factor V Leiden, factor II mutations, protein C and S deficiencies, is not significantly different in PAH or CTEPH, versus control subjects, 157 reviewed by Mehta et al. 158 However, other prothrombotic mechanisms, including enhanced platelets activation and reduced fibrinolytic function, occur in CTEPH. 145, 146 Platelets from CTEPH patients are hypersensitive to thrombin stimulation. 145 P-selectin and PAC-1 (activated GP IIb/IIIa) are markers of activated platelets. After thrombin stimulation, the percentage of P-selectin-positive and PAC-1-positive platelets in CTEPH patients (14.7% and 53.9%, respectively) was significantly higher versus controls (2.09% and 20.86%, respectively). 145 The activated platelets induce the expression of VCAM-1 (vascular cell adhesion molecule-1), 145 an important mediator of immune cells adhesion to the vascular endothelium. Increases in VCAM-1 are associated with development of PH. 159 After thrombin stimulation, the relative increase in platelet VCAM-1 expression was significantly higher in CTEPH patients (17.6-fold) than in controls (2.4-fold). 145 These findings suggest platelet dysfunction may be involved in the pathogenesis of CTEPH. If confirmed, this would change the therapeutic approach to this PH group, which currently focuses on inhibiting the clotting cascade.
Fibrinolytic Abnormalities
Thrombin also activates a plasma carboxypeptidase inhibitor, TAFI (thrombin-activatable fibrinolysis inhibitor). 160 TAFI removes the C-terminal lysines from fibrin and decreases its binding by tissue-type plasminogen activator and plasmin. 161 Thus, TAFI activation impairs fibrinolysis. 162 Plasma TAFI levels were significantly higher in CTEPH patients versus controls. 146 Furthermore, impairment of fibrinolysis in patients was improved with a TAFI inhibitor, CPI-2KR, suggesting TAFI as a potential therapeutic target in CTEPH. 146 TAFI can also be released from activated platelets. 145, 163 In CTEPH patients, TAFI released from activated platelets was markedly higher compared with that in controls. 146 Yaoita et al demonstrated that an inhibitor of platelet activation, prostaglandin E 1 , indirectly lowers TAFI levels in CTEPH patients.
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Conclusions
There remains inadequate preclinical focus on basic mechanisms and novel therapeutics for group 2 to 4 PH. The human experience to date suggests little therapeutic overlap of existing PH-targeted therapeutic agents among groups. Thus, the search for animal models that accurately recapitulate the disease phenotype for each PH group is important as a means of discovering new group-specific therapies and biomarkers. We have identified some knowledge gaps and listed corresponding future research directions in Table 4 .
